Mesalamine
 OpenBabel02212023462D

 11 11  0  0  0  0  0  0  0  0999 V2000
    0.7145    2.0625    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.7145    1.2375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4289    0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4289   -0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1434   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8579   -0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.1434   -1.2375    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.7145   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7145   -1.2375    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  2  0  0  0  0
  2 11  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  4  8  2  0  0  0  0
  5  6  2  0  0  0  0
  5  7  1  0  0  0  0
  8  9  1  0  0  0  0
  8 10  1  0  0  0  0
 10 11  2  0  0  0  0
M  END
>  <CdId>
374

>  <Mol Weight>
153.1354

>  <Formula>
C7H7NO3

>  <ID>
T0646

>  <Name>
Mesalamine

>  <Synonyms>
5-ASA;Mesalazine;5-Aminosalicylic acid

>  <CAS>
89-57-6

>  <Approved status>
FDA

>  <Disease>
Immune system

>  <Indication>
Inflammatory Bowel Disease

>  <Pathways>
Immunology/Inflammation; Metabolism; NF-¦ªb; Neuroscience

>  <Target>
COX inhibitor; Lipoxygenase inhibitor; MPO inhibitor; NF-¦ÊB inhibitor; PPAR agonist

>  <Receptor>
COX; ALOX5; MPO; NF-¦ÊB; PPAR¦Ã

$$$$
